1-[2,3-dihydroxy-6-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenyl]-2,2-dimethylpropan-1-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[2,3-dihydroxy-6-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenyl]-2,2-dimethylpropan-1-one
• 化学式: C₁₄H₂₁NO₄
• 分子量: 267.32
• InChiKey: PTSSJTTXBVCXEX-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  89.8
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• Dipivefrin orally disintegrating tablet formulations
  申请人：INSIGNIS THERAPEUTICS, INC.

  公开号：US11213484B2

  公开（公告）日：2022-01-04

  This disclosure provides orally disintegrating dipivefrin tablet (ODT) formulations, including ODT formulations containing L-dipivefrin HCl. The ODT formulations of the disclosure include 10 to 70% binder (wt %), 5 to 50% matrix former (wt %), and 1 to 20% taste masking agent (wt %). The ODT formulations of the disclosure rapidly provide epinephrine to a patient when administered. The disclosure also provides a method of treating a patient who has a condition responsive to epinephrine such as a cardiac event, asthma, croup, cancer, a microbial infection, Addison's disease, or an allergic reaction, particularly anaphylaxis by administering an orally disintegrating dipivefrin tablet formulations to the patient.

  本公开提供了口腔崩解地匹福林片剂（ODT）制剂，包括含有盐酸地匹福林的ODT制剂。本公开的 ODT 制剂包括 10% 至 70% 的粘合剂（重量百分比）、5% 至 50% 的基质成形剂（重量百分比）和 1% 至 20% 的掩味剂（重量百分比）。本公开的 ODT 制剂在给药时可迅速为患者提供肾上腺素。本公开还提供了一种治疗方法，通过向患有对肾上腺素有反应的疾病（如心脏病、哮喘、咳嗽、癌症、微生物感染、阿狄森氏病或过敏反应，特别是过敏性休克）的患者施用口腔崩解地匹福林片剂制剂来治疗该患者。
• DIPIVEFRIN ORALLY DISINTEGRATING TABLET FORMULATIONS
  申请人：INSIGNIS THERAPEUTICS, INC.

  公开号：US20200276114A1

  公开（公告）日：2020-09-03

  This disclosure provides orally disintegrating dipivefrin tablet (ODT) formulations, including ODT formulations containing L-dipivefrin HCl. The ODT formulations of the disclosure include 10 to 70% binder (wt %), 5 to 50% matrix former (wt %), and 1 to 20% taste masking agent (wt %). The ODT formulations of the disclosure rapidly provide epinephrine to a patient when administered. The disclosure also provides a method of treating a patient who has a condition responsive to epinephrine such as a cardiac event, asthma, croup, cancer, a microbial infection, Addison's disease, or an allergic reaction, particularly anaphylaxis by administering an orally disintegrating dipivefrin tablet formulations to the patient.
• PRODRUG COMPOSITIONS AND METHODS OF TREATMENT
  申请人：AQUESTIVE THERAPEUTICS, INC.

  公开号：US20210128511A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.